

**CURRICULUM VITAE**

**Garry Arthur Neil, M.D.**

**DATE OF BIRTH:** On request

**CITIZENSHIP:** United States of America

**MARITAL STATUS:** Married, three children

**SOCIAL SECURITY NUMBER:** On request

**ADDRESS:**

Global Head, Research and Development  
Medgenics  
435 Devon Park Drive  
Wayne, PA 19087

Telephone: +1 (610) 254-4208

FAX: +1 (610) 254-4202

█ █  
Email: [garry.neil@medgenics.com](mailto:garry.neil@medgenics.com)

Administrative Assistant: Mary Scavello  
[mary.scavello@medgenics.com](mailto:mary.scavello@medgenics.com)

**EDUCATION:**

9/70 - 4/74      University of Saskatchewan, Regina  
College of Arts and Science  
Bachelor of Science in Biology

9/74 - 5/79      University of Saskatchewan, Saskatoon  
College of Medicine  
Doctor of Medicine (with Distinction)

**POSTGRADUATE EDUCATION:**

7/79 - 6/80	University of Saskatchewan, Saskatoon University Hospital Straight Internship in Medicine
7/80 - 6/81	University of Saskatchewan, Saskatoon University Hospital Resident II in Medicine
7/81 - 2/82	University of Toronto St. Michael's Hospital Resident III in Medicine
3/82 - 6/82	University of Toronto St. Joseph's Hospital Chief Resident in Medicine
7/82 - 12/82	University of Toronto Toronto Western Hospital Fellow in Gastroenterology
1/83 - 6/83	University of Toronto Sunnybrook Hospital Fellow in Gastroenterology
7/83 - 12/83	University of Toronto Toronto General Hospital Senior Fellow in Gastroenterology
1/84 - 6/84	University of Toronto Mt. Sinai Hospital Senior Fellow in Gastroenterology
10/84 - 3/87	Research Institute of Scripps Clinic La Jolla, California Department of Immunology Post-Doctoral Fellow in Immunology Mentor: Norman R. Klinman, M.D., Ph.D. Research Institute of Scripps Clinic Professor, University of California, San Diego

**LICENSURE AND QUALIFICATIONS:**

5/79	Medical Council of Canada Examination (LMCC)
2/81	Licentiate of the Medical Council of Canada Number on request
6/83	Specialist Certification, Internal Medicine Royal College of Physicians of Canada

- 12/84 Specialist Certification, Gastroenterology  
Royal College of Physicians of Canada
- 11/85 Specialist Certification, Internal Medicine  
American Board of Internal Medicine  
Number on request
- 11/85 Specialist Certification, Gastroenterology  
American Board of Internal Medicine  
Number on request
- 3/81 - 10/92 General License, Province of Ontario  
Number on request
- 6/84 - 1/90 General License, Province of Saskatchewan  
Number on request
- 6/88 - 12/95 General License, State of Iowa  
Number on request
- 2/94 - present General License, State of Pennsylvania  
Number on request
- 10/88 -present DEA Registration  
Number on request
- 10/88 – 12/95 State of Iowa  
Controlled Substances Registration  
Number on request

**ACADEMIC APPOINTMENTS:**

- 3/87 - 7/88 Senior Staff Scientist and Clinical Associate Director  
Ludwig Institute for Cancer Research  
Toronto Branch, Toronto, Ontario, Canada
- 3/87 - 7/88 Assistant Professor  
Department of Medicine  
University of Toronto, Toronto, Ontario, Canada

8/88 - 6/93	Assistant Professor Internal Medicine (Gastroenterology-Hepatology) University of Iowa, Iowa City, IA
7/93 - 10/93	Associate Professor with Tenure Internal Medicine (Gastroenterology-Hepatology) University of Iowa, Iowa City, IA
7/95 – 12/99	Adjunct Associate Professor Department of Internal Medicine Division of Gastroenterology University of Pennsylvania, Philadelphia, PA

**CORPORATE APPOINTMENTS:**

9/93 - 6/94	Associate Director, Clinical Research (Gastrointestinal) Astra Merck Group, Merck and Co.
7/94 - 11/94	Director, Clinical Research (Gastrointestinal) Astra Merck Group, Merck & Co.
11/94 - 12/96	Director, Clinical Research (Gastrointestinal) Astra Merck, Inc., Wayne, Pa
5/95 - 12/96	Director, Medical Scientific Skill Center Astra Merck Inc., Wayne, PA
1/97 - 12/98	Executive Director, Medical Affairs Astra Merck Inc., Wayne, PA
1/98 - 8/98	Executive Director, Medical & Scientific Affairs Astra Merck Inc. Wayne, PA
9/98 – 6/99	Vice President, Medical & Scientific Affairs Astra Pharmaceuticals LP, Wayne, PA
7/99 – 12/99	Vice President, Clinical Research AstraZeneca Pharmaceuticals, Wilmington, DE
1/00 – 6/02	Vice President, Clinical Research and Development Merck KGaA, Darmstadt, Germany and EMD Pharmaceuticals Durham, NC
7/02 – 8/04	Senior Vice President, Global Drug Development Johnson and Johnson Pharmaceutical Research and Development Raritan, NJ
7/03 – 3/04	Global Head, Global Regulatory Affairs (concomitant position) Johnson and Johnson Pharmaceutical Research and Development Raritan, NJ

9/04 – 10/05	President Johnson and Johnson Pharmaceutical Research and Development, LLC Raritan, NJ
10/05 – 11/07	Group President Johnson and Johnson Pharmaceutical Research and Development, LLC Global Head, Cross Pharma Global Preclinical Development Global Head, Cross Pharma Global Chem/Pharm Raritan, NJ
11/07 – 8/12	Corporate Vice President Corporate Office of Science and Technology Johnson and Johnson New Brunswick, NJ
9/12 – 9/13	Partner Apple Tree Partners Princeton, NJ
1/13 – 9/13	Head, Research and Development Braeburn Pharmaceuticals Princeton, NJ
9/13 – Present	Adjunct Partner Apple Tree Partners Princeton, NJ
9/13 – Present	Global Head, Research & Development Medgenics Wayne, PA

**CORPORATE BOARDS AND COMMITTEES:**

7/02 – 11/07	Board Member Johnson and Johnson Pharmaceutical Research and Development, LLC
7/02 – 6/06	Member Johnson and Johnson Pharmaceuticals New Product Development Committee
7/06 – 11/07	Board Member J&J Global CNS/IM Franchise Board
7/02 – 12/04	Member Drug Evaluation Executive Committee Johnson and Johnson Pharmaceutical Research and Development Raritan, NJ (Committee disbanded 12/04)
10/02 – present	Board Member Johnson and Johnson Pharmaceutical Global Strategic Marketing

12/02 – 11/07	Chairman, Integrated Development Committee/ Development Management Committee Johnson and Johnson Pharmaceuticals
4/03 – 9/04	Chairman, Cross Pharma Drug Development Council Johnson and Johnson Pharmaceuticals
7/02 – 11/07	Member Johnson and Johnson Cross Pharma Research and Development Committee
1/05 – 8/13	Board member Johnson and Johnson Development Corporation
11/07 – 8/12	Member Johnson & Johnson Worldwide Research and Development Council
11/07 – 6/12	Member Johnson & Johnson Board of Directors Science and Technology Advisory Committee
6/12 – 8/12	Management coordinator Johnson & Johnson Board of Directors Science and Technology Committee

**OTHER APPOINTMENTS:**

10/05 – 8/13	Johnson & Johnson representative and current Chairman PhRMA S&R Executive Committee
5/06 – 8/13	Johnson & Johnson representative and current Chairman PhRMA Foundation Board
1/06 – 8/13	Member, Executive Committee PhRMA-NIH-FDA-FNIH Biomarker Consortium
7/05 – 12/07	Member, Board of Overseers Robert Wood Johnson Medical School New Brunswick, NJ
2/07 – 6/11	Vice Chair, Board of Trustees Newark Boys Chorus School Newark, NJ
11/07 - present	Board member and Head, Development Committee Reagan Udall Foundation for the FDA Washington, DC

11/07 – 8/12	Chairman, Scientific Advisory Board Center for Advanced Biotechnology and Medicine Rutgers University Piscataway, NJ
05/12 – present	Director, Foundation for the National Institutes of Health (FNIH) Washington, DC
8/12 – 03/14	Chairman, Board of Directors Transcelerate Biopharmaceuticals Inc. Philadelphia, PA
3/12 – 9/13	Member, Scientific Management Review Board National Institutes of Health Bethesda, MD

**MEMBERSHIPS:**

7/79 -	American College of Physicians (Fellow)
7/82 -	American Gastroenterology Association
7/82 -	Canadian Association of Gastroenterologists
6/83 -	Royal College of Physicians of Canada (Fellow)
1/85 -	American Association of Immunologists (Active Member)
3/89 -	Gastroenterology Research Group
12/89 -	American Society for Gravitational and Space Biology
1/90 -	American Federation for Clinical Research
1/91 -	Society for Mucosal Immunology
4/93 -	Clinical Immunology Society
5/93 -	Federation of American Societies for Experimental Biology
11/93 -	American Association for the Study of Liver Disease
11/93 -	Central Society for Clinical Research
2/94 -	American College of Gastroenterology (Fellow)
4/94 -	American Academy of Pharmaceutical Physicians
9/95 -	American Society for Microbiology
2/99 -	American College of Clinical Pharmacology
12/06 -	Society for Clinical Trials

**HOSPITAL PRIVILEGES AND APPOINTMENTS:**

7/84 - 12/84	Plains Health Center Regina, Saskatchewan Consultant in Gastroenterology and Medicine
7/84 - 12/84	Regina General Hospital Regina, Saskatchewan Consultant in Gastroenterology and Medicine
7/84 - 12/84	Pasqua Hospital Regina, Saskatchewan Consultant in Gastroenterology and Medicine
1/87 - 7/88	Princess Margaret Hospital Toronto, Ontario Associate Consultant, Medicine
7/87 - 7/88	Mount Sinai Hospital Toronto, Ontario Associate Staff, Gastroenterology
8/88 - 10/93	University Hospitals and Clinics University of Iowa, Iowa City, Iowa Staff Physician, Internal Medicine, Gastroenterology-Hepatology
10/88 - 10/93	Veterans Administration Hospital Iowa City, Iowa Staff Physician, Internal Medicine, Gastroenterology-Hepatology

**HONORS AND AWARDS:**

9/73 - 4/74	University of Saskatchewan Undergraduate Scholarship
9/74 - 5/79	Province of Saskatchewan Medical Bursary
9/76 - 5/79	University of Saskatchewan, College of Medicine Undergraduate Scholarship
5/79	The Hugh McLean Medal in Surgery
5/79	The University of Saskatchewan Medal in Medicine
10/84 - 3/87	Medical Research Council of Canada Postdoctoral Fellowship
7/86 - 3/87	American Liver Foundation Postdoctoral Fellowship
9/96	Astra Merck Silver Management Award



2/97	Astra Merck Silver Management Award
5/97	Astra Merck Quality Solutions Award of Excellence
6/97	Astra Merck Silver Management Award
9/07	Honored by Congressman Scott Garrett of New Jersey, statement in Congressional Record
10/07	Discoverer's Award, American Geriatrics Society
10/13	FDA Commissioner's Special Citation

**EDITORIAL/REVIEW ACTIVITIES:**

1989 - 1990	Editor, <i>Spotlight on Biotechnology</i>
1992	Manuscript Referee, <i>Cellular Immunology</i>
1992	Manuscript Referee, <i>Biotechniques</i>
1993	Manuscript Referee, <i>Digestive Diseases and Sciences</i>
1993	Manuscript Referee, <i>Gastroenterology</i>
1994	Manuscript Referee, <i>Naturwissenschaften</i>
1994	Manuscript Referee, <i>Journal of Immunology</i>
1995	Manuscript Referee, <i>Experimental Cell Research</i>
1995	Manuscript Referee, <i>Journal of Immunological Methods</i>
1995	Manuscript Referee, <i>Naturwissenschaften</i>
1995	Manuscript Referee, <i>Digestive Diseases</i>
1995	Manuscript Referee, <i>Gastroenterology</i>
1996	Manuscript Referee, <i>Alimentary Pharmacology and Therapeutics</i>
1997	Manuscript Referee, <i>Alimentary Pharmacology and Therapeutics</i>
1998	Manuscript Referee, <i>Alimentary Pharmacology and Therapeutics, Digestive Diseases and Sciences, American Journal of Gastroenterology</i>
1999	Manuscript Referee, <i>Alimentary Pharmacology and Therapeutics, Digestive Diseases and Sciences, American Journal of Gastroenterology</i>
2000	Manuscript Referee, <i>American Journal of Gastroenterology</i>
2001	Manuscript Referee, <i>American Journal of Gastroenterology</i>

2002 Manuscript Referee, *American Journal of Gastroenterology*

**STUDY SECTIONS:**

6/93 - 10/95 Veterans Administration  
Merit Review Board  
Gastroenterology

10/95- 10/96 Chairman  
Veterans Administration  
Merit Review Board  
Gastroenterology

10/93 - 1/00 National Cancer Institute  
Ad Hoc Review Panel Member

5/98 – 1/00 National Institute of Diabetes, Digestive and Kidney Diseases  
Ad Hoc Review Panel Member

**SESSION CHAIRMANSHIPS:**

10/91 Session Chairman, "Electrical Manipulation of the Cell"  
International Biotechnology Conference,  
San Francisco, CA

10/92 Session Co-Chairman, "Surrogate Markers of Human Disease"  
International Biotechnology Conference,  
San Francisco, CA

4/96 Scientific Advisory Committee  
IBC Conference on *H. pylori*  
Philadelphia, PA

1/97 Chairman  
IBC Conference on *H. pylori*  
Washington, DC

3/07 Session Chair  
EU DIA  
Biomarkers Consortium  
Vienna, Austria

10/07 Session Chair  
PhRMA S&R Committee Annual Meeting  
Washington, DC

**OTHER PROFESSIONAL ACTIVITIES:**

5/88 - 6/94	Calypte Biotechnology, Inc. Scientific Advisory Board
3/89 - 3/90	Baxter Scientific Products Scientific Advisory Board
5/89 - 10/93	G.D. Searle Gastroenterology Faculty Member
5/89 - 10/93	Merck & Co. Gastroenterology Faculty Member
5/90 - 10/93	Smith Kline Beecham Gastroenterology Faculty Member
9/00 – 6/03	Chronix Biomedical Board Member

**GRANTS AND FINANCIAL SUPPORT:**

10/84 - 1/87	Medical Research Council of Canada "Single Cell Analysis of the Murine B cell Repertoire" Post-Doctoral Fellowship \$95,000
1/87 - 8/88	Ludwig Institute for Cancer Research "Immunological Markers of Human Colon Cancer" Principal Investigator \$185,000
10/88 - 9/90	Canadian Foundation for Ileitis and Colitis "Molecular Biology of a Human Intestinal Stem Cell Expressed Gene" Co-Principal Investigator \$43,200
10/89 - 3/94	NASA, NASA-18433 "Enhanced Hybridoma Production Under Microgravity" Co-Principal Investigator \$698,000
2/90 - 6/91	G.D. Searle "The Incidence, Outcome and Associated Risk Factors of NSAID-induced Upper Gastrointestinal Bleeding" Principal Investigator \$35,000
7/90 - 6/93	NIH, RO1 CA37287 "Nutritional Prevention of Adenomatous Polyps in the colon".

Co-Investigator (P.I.: J.A. Baron,, Dartmouth Medical Center):  
\$252,105

7/90 - 6/93 NIH, UO1 CA46927-05  
"Calcium Supplementation in the Prevention of Neoplastic Polyps".  
Co-Investigator (P.I.: J.A. Baron,, Dartmouth Medical Center):  
\$264,000

7/91 - 6/92 G.D. Searle  
"Misoprostol Ulcer Complications Outcome and Safety Assessment",  
Principal Investigator, U. of Iowa,  
\$5,000

4/92 - 3/93 Carver Trust  
"The Human Immunoglobulin and T Cell Receptor Variable  
Region Gene Repertoire in the SCID-Hu Chimera Model"  
Principal Investigator:  
\$12,000

3/93 - 3/94 NIH, Consortium 1PO50 AI3061  
"Human Immune Responses in the SCID-Hu Chimera"  
Principal Investigator:  
\$49,500

6/93 - 6/94 Central Investment Fund for Research Enhancement  
"A SCID Mouse Model for Human Parvovirus B19 Infection"  
Co-Investigator:  
\$10,000

**ACADEMIC COMMITTEES:**

9/89 - 10/93 University of Iowa College of Medicine Flow Cytometry Committee

10/90 - 10/93 University of Iowa Hawkeye Advisory Committee

8/91 - 10/93 University of Iowa Department of Internal Medicine  
Resident Selection Committee

8/91 - 10/93 University of Iowa College of Medicine  
Comprehensive Cancer Center Program Committee

2/92 - 2/93 International Biotechnology Exposition and Scientific Meeting  
Program Committee

4/93 - 10/93 Center for Health Effects of Environmental Contamination Advisory  
Committee

4/93 - 10/93 University of Iowa Pharmacy and Therapeutics Committee  
Biotechnology Subcommittee

**PUBLICATIONS:*****Papers***

1. Bear, R.A. and Neil, G.A. A clinical approach to common electrolyte problems: 1. Hyponatremia. *Can. Med. Assoc. J.* 128(10):1171-1174, 1983.
2. Bear, R.A. and Neil, G.A. A clinical approach to common electrolyte problems: 2. Potassium imbalances. *Can. Med. Assoc. J.* 129(1):28-31, 1983.
3. Neil, G.A., Lukie, B.E., Cockcroft, D.W. and Murphy, F. Lymphocytic interstitial pneumonitis and abdominal lymphoma complicating celiac sprue. *J. Clin. Gastroenterol.* 8(3):282-285, 1986.
4. Neil, G.A. and Klinman, N.R. Repertoire expression in surface immunoglobulin negative bone marrow B cell precursors. *Intern. Rev. Immunol.* 2(1):307-320, 1987.
5. Langlet, C.R., Neil, G.A. and Sherman, L.A.. The mechanism of anti-Lyt-2 antibody inhibition of antibody directed lysis by cytotoxic T lymphocytes. *J. Immunol.* 139(11):3590-3596, 1987.
6. Neil, G.A. and Urnovitz, H.B. Recent advances in hybridoma technology. *Trends Biotechnol.* 6(9):209-213, 1988.
7. Stopper, H., Zimmermann, U. and Neil, G.A. Increased efficiency of transfection of murine hybridoma cells with DNA by electropermeabilization. *J. Immunol. Meth.* 109(1):145-151, 1988.
8. Neil, G.A. and Bruce, W.R. An experimental approach to colorectal cancer prevention. *Gastroenterol. Clin. N. America.* 17(4):917-930, 1988.
9. Schmitt, J., Zimmermann, U. and Neil, G.A. Efficient generation of stable antibody forming hybridoma cells by electrofusion. *Hybridoma.* 8(1):107-115, 1989.
10. Schnettler, R., Gessner, P., Zimmermann, U., Neil, G.A., Urnovitz, H.B. and Sammons, D.W.. Increased efficiency of somatic cell hybrid generation under microgravity conditions. *Appl. Micrograv. Tech.* 2(1):3-9, 1989.
11. Kowalski, M., Hannig, K., Klöck, G., Gessner, P., Zimmermann, U., Neil, G.A. and Sammons, D.W. Electrofused mammalian cells analyzed by free-flow electrophoresis. *Biotechniques* 9(3):332-341, 1990.
12. Zimmermann, U., Schnettler, R., Klöck, G., Sammons, D.W., Neil, G.A. and Klinman, N.R. Electrofusion of mammalian cells in microgravity. *W.P.F. Bull.* 4:192-195, 1990.
13. Fung, L.S., Neil, G.A., Leibowitz, J., Cole, E.H., Chung, S., Crow, A. and Levy, G.A. Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection. *J. Biol. Chem.* 266(3):1789-1795, 1991.
14. Gregoire, R., Yeung, K.S., Stadler, J., Stern, H.S., Kashtan, H., Neil, G.A. and Bruce, W.R. The effect of high-fat and low-fiber meals on the cell proliferation activity of the colorectal mucosa. *Nutrition and Cancer* 15(1):21-27, 1991.
15. Neil, G.A., Blum, A. and Weinstock, J.V. Substance P but not vasoactive intestinal peptide modulates immunoglobulin secretion in granulomas of murine schistosomiasis. *Cell. Immunol.* 135:394-401, 1991.

16. Zimmermann, U., Neil, G.A., Klöck, G., Schnettler, R., Klinman, N.R. and Sammons, D.W. Cell culture, cell activation, cell fusion and hybridoma production in microgravity. *W.P.F. Bull.* 5:201-205, 1991.
17. Zimmermann, U., Klöck, G., Gessner, P., Sammons, D.W., and Neil, G.A. Microscale production of hybridomas by hypo-osmolar electrofusion. *Hum. Antibod. Hybridomas* 3(1):14-18, 1992.
18. Gregoire, R.C., Kashtan, H., Stern, H.S., Yeung, K.S., Stadler, J., Neil, G.A., Furrer, R., Langley, S. and Bruce, W.R. The effect of lowering fecal pH on the rate of proliferation of the normal colonic mucosa. *Surg. Oncol.* 1(1):43-47, 1992.
19. Sammons, D.W., Zimmermann, U., Klinman, N.R., Emmons, S.R., Gessner, P. and Neil, G.A. An experimental system for determining the influence of microgravity on B lymphocyte activation and cell fusion. *Adv. Space Res.* 12(1):363-372, 1992.
20. Johlin, F.C., LaBrecque, D.R. and Neil, G.A. Omeprazole heals ulcers associated with endoscopic injection sclerotherapy. *Dig. Dis. Sci.* 37(9):1373-1376, 1992.
21. Neil, G.A., Summers, R.W., Cheyne, E.A., Carpenter, C., Kansas, G.S., Huang, W. and Waldschmidt, T.J.. CD5<sup>+</sup> B cells are decreased in the peripheral blood of patients with Crohn's disease. *Dig. Dis. Sci.* 37(9):1390-1395, 1992.
22. Neil, G.A. and Sammons, D.W. Immunization of SCID-HU-PBL mice and generation of anti-hepatitis B surface antigen specific hybridomas by electrofusion. *Hum. Antibod. Hybridomas.* 3(4):201-205, 1992.
23. Neil, G.A. and Zimmermann, U. Electrofusion. *Methods Enzymol.* 220:174-197, 1993.
24. Neil, G.A. and Zimmermann, U. Electroinjection. *Methods Enzymol.* 221:339-361, 1993.
25. Hardarson, S., LaBrecque, D.R., Mitros, F.A., Neil, G.A. and Goeken, J.A. Anti-neutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. *Am. J. Clin. Pathol.* 99:277-281, 1993.
26. Johlin, F.C. and Neil, G.A. Drainage of the gallbladder in patients with acute acalculous cholecystitis by transpapillary endoscopic cholecystotomy. *Gastrointest. Endosc.* 39:645-651, 1993.
27. Sutherland, D.B., Varilek, G. W. and Neil, G.A. Identification and characterization of the rat intestinal epithelial cell (IEC-18) interleukin 1 receptor. *Am. J. Physiol.* 266(5):C1198-C1203, 1994.
28. Neil, G.A., Summers, R.W., Cheyne, E.A., Carpenter, C., Kansas, G.S., Huang, W. and Waldschmidt, T.J. Analysis of T lymphocyte subpopulations in Crohn's disease by 3 color flow cytometry. *Dig. Dis. Sci.* 39(9):1900-1908, 1994.
29. Kresina, T.F., Wisnewski, A., Love-Homan, L., Ramirez, B. and Neil, G.A. Induction of hepatic pathology in SCID-Hu mice engrafted with peripheral blood lymphocytes of patients with *Schistosoma japonica*. *J. Infect. Dis.* 170:733-736, 1994.
30. Varilek, G.W., Neil, G.A. and Bishop, W.P. CaCo-2 cells express type I interleukin-1 receptors: ligand binding enhances proliferation. *Am. J. Physiol.*, 267(12):G1101-G1107, 1994.
31. Laskin, C.A., Chuma, A., Angelov, L., Neil, G.A., Levy, G.A., Mason, N., Soloninka, C. and Cole, E. Sera from habitual aborters induce monocyte procoagulant activity: A lymphocyte-dependent event. *Clin. Immunol. Immunopath.* 73: 235-244, 1994.

32. Cole, E.H., Neil, G.A., Myers-Mason, N., Fung, L.S. and Levy, G.A. Characterization of the procoagulant-inducing factor derived from the plasma of BXSB mice. *J. Autoimmunity* 8:47-49, 1995.
33. Zimmermann, U., Love-Homan, L., Gessner, P., Clark, D., Johlin, F.C. and Neil, G.A. Generation of a human monoclonal antibody to hepatitis C virus, JRA1 by activation of peripheral blood lymphocytes and hypo-osmolar electrofusion. *Hum Antibodies Hybridomas* 6(2):77-80, 1995.
34. Varilek, G.W., Neil, G.A., Bishop, W.P., Lin, J. and Pantazis, N.J. Nerve growth factor (NGF) synthesis by intestinal epithelial cells. *Am. J. Physiol.*, 269:G445-G452, 1995.
35. Laine, L., Stein, C. and Neil, G.A. Limited efficacy of omeprazole-based dual and triple *H. pylori* therapy: a randomized trial employing "optimal" dosing. *Am. J. Gastroenterol.* 90:1407-1410, 1995.
36. Graham, K.S., Malaty, H., Genta, R.M., Cole, R.A., Neil, G.A. and Graham, D.Y. Omeprazole amoxicillin combinations for treatment of *Helicobacter pylori* infection. *Am. J. Gastroenterol.* 90:1415-1418, 1995.
37. Laine, L., Estrada, R., Trujillo, M., Fukunaga, K. and Neil, G.A. Randomized comparison of 7, 10 and 14 days of omeprazole, amoxicillin and clarithromycin for treatment of *H. pylori*. *Aliment. Pharmacol. Ther.* 10:1029-1033, 1996.
38. Neil, G.A. for the American College of Gastroenterology Subcommittee on FDA-Industry Relations. Do ulcers burn out or burn on? Managing duodenal ulcer diathesis in the *H. pylori* era. *Am. J. Gastroenterol.*, 92:387-393, 1997.
39. Neil, G.A., Suchower, L.J., Ronca, P.D., Skoglund, M.L. Timing of *H. pylori* (HP) assessment following treatment. *Helicobacter*, 2:13-20, 1997.
40. Laine, L., Frantz, J.E., Baker, A., Neil, G.A.. A United States multicentre trial of dual and proton pump inhibitor-based therapies for *H. pylori* eradication. *Aliment. Pharmacol. Ther.* 11:913-917, 1997.
41. Laine, L., Johnson, E., Suchower, L., Ronca, P., Hwang, C. and Neil, G.A.. U.S. double-blind, controlled trials of omeprazole and amoxicillin (OA) for treatment of *H. pylori*. *Aliment. Pharmacol. Ther.* 12:377-382, 1998.
42. Laine, L., Suchower, L., Johnson, E., Ronca, P., and Neil, G.A. Accuracy of CLO test after *H. pylori* therapy. *Gastrointestinal Endoscopy* 47:250-253, 1998.
43. Neil, G.A., Suchower, L., Johnson, E.W., Ronca, P., Skoglund, M.L. *H. pylori* (HP) eradication as a surrogate marker for duodenal ulcer (DU) relapse reduction. *Aliment. Pharmacol. Ther.*, 12:613-618, 1998.
44. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Twice daily 10-day triple therapy with omeprazole, amoxicillin and clarithromycin for *H. pylori* eradication in duodenal ulcer disease: results of 3 multicenter double-blind U.S. trials. *Am. J. Gastroenterol.*, 93:2106-2112, 1998.
45. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Low rate of emergence of clarithromycin resistant *H. pylori* with amoxicillin cotherapy: results from 3 multicenter double-blind U.S. Trials. *Aliment. Pharmacol. Ther.*, 12:887-892, 1998.

46. Laine, L., Estrada, R., Trujillo, M., Yeramian, P., Smith, S. and Neil, G.A. Once daily therapy for *H. pylori*: a randomized comparison of 4 regimens. *Am J Gastroenterol.* 94(4):962-6, 1999.
47. Laine, L., Sugg, J., Suchower, L. and Neil, G.A. Endoscopic biopsy requirements for post-treatment diagnosis of *Helicobacter pylori*. *Gastrointest Endosc.* 51(6):664-9, 2000.
48. Eichler, H.G et al Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval. *Clinical Pharmacology & Therapeutics* 91 3, 426–437, 2012.
49. Gill, D. and Neil, GA. Transclerate Biomedical Inc. *New York Health Forum.* Spring (4) PP 45-50, 2013.

### **Book Chapters**

1. Bear, R.A., Neil, G.A. and Hierlihy, P.J. The kidney and neoplastic disease in Levine, D.Z. (ed.), *Care of the Renal Patient.* W.B. Saunders, Toronto. pp 388-397, 1983.
2. Neil, G.A. and Weinstock, J.V. Gastrointestinal manifestations of systemic diseases. In Yamada, T., Alpers, D.H., Owyang, C., Powell, D.W. and Silverstein, F.E. (eds). *Textbook of Gastroenterology.* J.B. Lippincott, Philadelphia, pp.2135-2157, 1991.
3. Neil, G.A. and Weinstock, J.V. Gastrointestinal manifestations of systemic diseases. In Yamada, T., Alpers, D.H., Owyang, C., Powell, D.W. and Silverstein, F.E. (eds). *Atlas of Gastroenterology.* J.B. Lippincott, Philadelphia, pp.400-403, 1991.
4. Neil, G.A. and Weinstock, J.V. Gastrointestinal manifestations of systemic diseases. In Yamada, T., Alpers, D.H., Owyang, C., Powell, D.W. and Silverstein, F.E. (eds.) *Textbook of Gastroenterology (2nd Edition).* J.B. Lippincott, Philadelphia, pp. 2419-2454, 1995
5. Levine, J.S., Neil, G.A. and Weinstock, J.V. Gastrointestinal manifestations of systemic diseases. In Yamada, T., Alpers, L. Laine D.H., Owyang, C., Powell, D.W. (eds). *Atlas of Gastroenterology (2nd Edition).* J.B. Lippincott, Philadelphia, 1999.
6. Kresina, T.F., Neil, G.A. and Foung, S.K.H. Human monoclonal antibodies and immune modulation in viral hepatitis, schistosomiasis and HTLV infection. *HuMoAb and Immune Regulation.* pp. 237-254, 1997.

### **Books**

1. Zimmermann, U. and Neil, G.A. (Eds). *Electromanipulation of the cell.* CRC Press, Boca Raton, FL, 1996

### **Abstracts**

1. Neil, G.A. and Jeejeebhoy, K.N. Successful use of misoprostol in hemorrhagic gastritis. *Gastroenterology* 86(5):1194, 1984.
2. Neil, G.A., Staerz, U.D. and Klinman, N.R. L3T4<sup>+</sup> Lyt 2<sup>-</sup> T cells armed with DNP substituted anti-T cell receptor antibodies provide help for anti-DNP responses in vitro. *Proc. Fourth Inter. Congress*



*Immunol.*, 3:13:14, 1986.

3. Langlet, C.R., Neil, G.A. and Sherman, L.A. Anti-Lyt-2 inhibition of cytolysis that is independent of class I recognition. *J. Cell. Biochem.* 11:274, 1987.
4. Neil, G.A., Angelov, L.A. and Klinman, N.R. B cell activation by anti-T cell receptor conjugate stimulated CD4<sup>+</sup> cells in vitro. *FASEB J.* 3 (4):A1114, 1989.
5. Neil, G.A. T cell help mediated by anti-T cell receptor monoclonal antibodies. *Midwest Gut Club meeting*, Chicago, IL, March 8, 1989.
6. Stern, H., Gregoire, R., Yeung, K.S., Neil, G.A., Furrer, R. and Bruce, W.R. A randomized controlled trial of sodium sulfate and dietary fiber on fecal pH and mucosal risk factors for colon cancer. *Proc. Amer. Soc. Cancer Res.* 30:232, 1989.
7. Stern, H., Gregoire, R., Yeung, K.S., Neil, G.A., Furrer, R. and Bruce, W.R. A randomized controlled trial of sodium sulfate and dietary fiber on fecal pH and mucosal risk factors for colon cancer. *Clin. Invest. Med.* 12(4):B41, 1989.
8. Chung, S.W., Sinclair, S.B., Fung, L.S., Leibowitz, J., Neil, G.A., Cole, E. and Levy, G.A. Identification and regulation of the murine hepatitis virus induced prothrombinase. *FASEB J.* 4:1230, 1990.
9. Neil, G.A., Blum, A. and Weinstock, J.V. Substance P but not vasoactive intestinal peptide modulates immunoglobulin secretion in granulomas of murine schistosomiasis. *Gastroenterology.* 98:A466, 1990.
10. Sammons, D.W., Zimmermann, U., Klinman, N.R. and Neil, G.A. An experimental system for determining the influence of microgravity on B lymphocyte activation and cell fusion. *COSPAR XXVII*, The Hague, Netherlands, June 29, 1990.
11. Zimmermann, U., Schnettler, R., Klöck, G., Sammons, D.W., Neil, G.A. and Klinman, N.R. Electrofusion of mammalian cells. *COSPAR XXVII*, The Hague, Netherlands, June 29, 1990.
12. Neil, G.A., Saunders, T. and Sammons, D.W. Activation of primary and secondary murine B cell precursors with anti-CD3 MAb conjugated beads in vitro. *Amer. Soc. Grav. Space Biol. Bull.* 1990.
13. Neil, G.A. Rat intestinal epithelial cells secrete IL-6. *J. Cell Biol.* 111(5):187A, 1990.
14. Neil, G.A., Synn, S. and LaBrecque, D.R. The effect of IL-1 on rat intestinal epithelial cell proliferation. *Gastroenterology.* 100:A132, 1991.
15. Hardarson, S., LaBrecque, D.R., Mitros, F.A., Neil, G.A. and Goeken, J. Anti-neutrophil cytoplasmic antibody (ANCA) associated with ulcerative colitis and sclerosing cholangitis. *Gastroenterology.* 100:A585, 1991.
16. Neil, G.A., Summers, R.W., Cheyne, B.A. and Waldschmidt, T.J. Analysis of T lymphocyte subpopulations in Crohn's disease by 3 color flow cytometry. *Gastroenterology* 100:A603, 1991.
17. Neil, G.A., Summers, R.W., Cheyne, B.A. and Waldschmidt, T.J. CD5<sup>+</sup> B cells are decreased in the peripheral blood of patients with Crohn's disease. *Gastroenterology* 100:A603, 1991.
18. Johlin, F.C., LaBrecque, D.R. and Neil, G.A. Omeprazole in the healing of endoscopic injection sclerotherapy associated mucosal ulcers. *Gastroenterology* 100:A756, 1991.

19. Varilek, G.W., Neil, G.A., Antisdell, B. and Pantazis, N.J. Cell lines derived from intestinal epithelial cells synthesize nerve growth factor in culture. *Soc. for Neuroscience Abstr.* 17 (1-2), 1991.
20. LaBrecque, D.R., Neil, G.A., Jacobson, P., Bethell, D.R., Kink, J. and Todd, T.J.. The Pandex HCV paramagnetic virus particle assay (MP assay) - a highly sensitive new technique for hepatitis C virus (HCV). *Clin. Res.*, 39:743A, 1991.
21. Neil, G.A., Johlin, F.C., Garner, L. and Zimmerman, B. Risk factors associated with upper gastrointestinal bleeding - a case control study. *Gastroenterology* 102:A133, 1992.
22. Varilek, G.W., Bishop, W. and Neil, G.A. IL-1 enhances the proliferation of human colon cancer cells *in vitro*. *Gastroenterology* 102:A583, 1992.
23. Neil, G.A. Human immune responses to recombinant hepatitis B surface antigen in the SCID-Hu mouse model. *Gastroenterology* 102:A860, 1992.
24. Varilek, G.W., Bishop, W., Sutherland, D. and Neil, G.A. IL-1 $\beta$  stimulates proliferation of the human intestinal cell line CaCo-2. *Trends in Inflammatory Bowel Disease, Falk Symposium 66*, Quebec City, Que, June, 1992.
25. Wisnewski, A.V., Love-Homan, L., Neil, G.A. and Kresina, T.F. The immune repertoire of *Schistosoma japonica* in SCID-Hu-PBL mice. *Amer. J. Trop. Med. Hyg.* 47:130, 1992.
26. Varilek, G.W., Neil, G.A. and Bishop, W. Caco-2 expresses an interleukin-1 receptor. *Gastroenterology* 104:A287, 1993.
27. Wisnewski, A.V., Neil, G.A., Love-Homan, L., and Kresina, T.F. The immune repertoire of *Schistosoma japonica* in SCID-Hu-PBL mice. *Clin. Res.* 41:A382, 1993.
28. Neil, G.A., Love-Homan, L., Summers, K., Sammons, D.W. and Lewis, M.L. Human splenic B cell activation *in vitro* is not impaired in  $\mu$ g. *Amer. Soc. Gravitational Space Biol.*, Washington, DC, Oct., 1993.
29. Wisnewski, A., Love-Homan, L., Kresina, T., and Neil, G.A. Hepatic fibrosis in SCID-Hu mice engrafted with PBL from patients with *Schistosomiasis japonica*. *Hepatology* 18:A170, 1993.
30. Zimmermann, U., Love-Homan, L., Gessner, P., Clark, D., Johlin, F.C. and Neil, G.A. Generation of a human monoclonal antibody to hepatitis C virus, JRA1 by activation of peripheral blood lymphocytes and hypo-osmolar electrofusion. *Hepatology* 18:265A, 1993.
31. Johnson, E.W., Suchower, L.J., Dancer, N.A., Joelsson, B.E. and Neil, G.A. Omeprazole plus amoxicillin (dual) therapy for *H. pylori* infection: a review and meta-analysis of the literature. *Am. J. Gastroenterol.* 89:A325, 1994.
32. Chalmers, T.C., Ross, S.D., Neil, G.A., Lau, J., Kupelnick, B. and Whiting, G. A year after the NIH consensus statement on eradication of *H. pylori* in peptic ulcer disease. How best to do it? *Gastroenterology* 108:A8, 1995.
33. Graham, K.S., Malaty, H.M., El-Zimaity, R.M., Genta, R.M., Cole, R.A., Yousti, M.M., Al-Assi, M.T., Neil, G.A. and Graham, D.Y. Variability with omeprazole-amoxicillin combinations for treatment of *Helicobacter pylori* infection. *Gastroenterology* 108:A104, 1995.

34. Laine, L., Bartizal, K., Kong, L., Scott, P. and Neil, G.A. Evidence against oral-oral transmission of *H. pylori*: lack of salivary *H. pylori* by polymerase chain reaction (PCR). *Gastroenterology* 108:A141, 1995.
35. Laine, L., Stein, C. and Neil, G.A. Limited efficacy of omeprazole-based dual and triple *H. pylori* therapy: a randomized trial employing "optimal" dosing. *Gastroenterology* 108:A142, 1995.
36. Han, J.Q., Schmidt, W., Wu, P., LaBrecque, D., Neil, G.A. and Stapleton, J.T. Antibody captures HCV RNA-containing complexes from human sera. *Abstracts Interscience Conference on Antimicrob. Agents Chemotherapy* 35:194, 1995.
37. Neil, G.A., Suchower, L., Johnson, E.W., Ronca, P., Skoglund, M.L. Timing of *H. pylori* (HP) assessment following treatment. *Am. J. Gastroenterol.* 90:1588, 1995.
38. Neil, G.A., Suchower, L., Johnson, E.W., Ronca, P., Skoglund, M.L. *H. pylori* (HP) eradication as a surrogate marker for duodenal ulcer (DU) relapse reduction. *Am. J. Gastroenterol.* 90:1588, 1995.
39. Laine, L., Estrada, R., Trujillo, M., Fukunaga, K. and Neil, G.A. Randomized comparison of 7, 10 and 14 days of omeprazole, amoxicillin and clarithromycin for treatment of *H. pylori*. *Gastroenterology* 110:A168, 1996.
40. Varilek, G.W., Labrecque, D.R., Lager, D., Bishop, W.P. and Neil, G.A. Interleukin-1beta (IL-1 $\beta$ ) enhances proliferation of murine duodenal crypt cells. *Gastroenterology* 110:A1129, 1996.
41. Laine, L., Johnson, E., Suchower, L., Ronca, P., Hwang, C. and Neil, G.A.. Double-blind, controlled trials of omeprazole and amoxicillin (OA) for treatment of *H. pylori*. *Gastroenterology* 112:A191, 1997.
42. Laine, L., Frantz, J.E., Baker, A., Neil, G.A.. Randomized comparison of dual therapies and PPI-based triple therapies for *H. pylori* eradication. *Gastroenterology* 112:A192, 1997.
43. Laine, L., Suchower, L., Johnson, E., Ronca, P., and Neil, G.A. Accuracy of CLO test after *H. pylori* therapy. *Gastroenterology* 112:A191, 1997.
44. Laine, L., Estrada, R., Trujillo, M., Yeramian, P., Smith, S. and Neil, G. Once daily therapy for *H. pylori*: a randomized comparison of 4 regimens. *Gastroenterology* 114:A192, 1998.
45. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Twice daily 10-day triple therapy with omeprazole, amoxicillin and clarithromycin for *H. pylori* eradication in duodenal ulcer disease: results of 3 multicenter double-blind U.S. trials. *Gastroenterology* 114:A193, 1998.
46. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Reduced risk of clarithromycin resistant *H. pylori* with amoxicillin cotherapy: results from 3 multicenter double-blind U.S. Trials. *Gastroenterology* 114:A193, 1998.
47. Laine, L., Estrada, R., Trujillo, M., Yeramian, P., Smith, S. and Neil, G. Once daily therapy for *H. pylori*: a randomized comparison of 4 regimens. *EHPSEG*, Budapest, Sep, 4, 1998.
48. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Twice daily 10-day triple therapy with omeprazole, amoxicillin and clarithromycin for *H. pylori* eradication in duodenal ulcer disease: results of 3 multicenter double-blind U.S. trials. *EHPSEG*, Budapest, Sep, 4, 1998.

49. Laine, L., Suchower, L., Connors, A., Frantz, J. and Neil, G.A. Reduced risk of clarithromycin resistant *H. pylori* with amoxicillin cotherapy: results from 3 multicenter double-blind U.S. Trials. *EHPSPG*, Budapest, Sep. 4, 1998

**Invited Lectures and Talks**

1. Neil, G.A. Non-A Non-B hepatitis. *Medical Grand Rounds*, University of Saskatchewan, Saskatoon, Sask, Oct 14, 1983.
2. Neil, G.A. The war of winds - pathophysiology and management of "irritable bowel syndrome", *Medical Grand Rounds*, Mt. Sinai Hospital, Toronto, Ont., Feb. 15, 1984.
3. Neil, G.A. Enterotoxin induced diarrhea syndromes, *Medical Grand Rounds*, Mt. Sinai Hospital, Toronto, Ont., May 16, 1984.
4. Neil, G.A. and Jeejeebhoy, K.N. Misoprostol in hemorrhagic gastritis. *Misoprostol Investigators Meeting*, New Orleans, LA, May 19, 1984.
5. Neil, G.A. Directed T cell help in vitro using anti-T cell receptor antibodies. Invited Lecture. *Lehrstuhl für Biotechnologie, University of Würzburg*, Würzburg, Germany, Oct. 23, 1985.
6. Neil, G.A. L3T4<sup>+</sup> Lyt 2<sup>-</sup> T cells armed with DNP substituted anti-T cell receptor antibodies provide help for anti-DNP responses in vitro. *Immunology Research Seminar*, Research Institute of Scripps Clinic, La Jolla, CA, Jan. 10, 1986.
7. Neil, G.A. T cell - B cell collaboration *in vitro*. *Immunology Research Seminar*, State University of New York, Stonybrook, NY, Jan. 27, 1986.
8. Neil, G.A. *In vitro* immunization of murine B cells. *Gastroenterology Grand Rounds*, University of Calgary, Calgary, Alta, Feb. 8, 1986.
9. Neil, G.A. A novel approach to *in vitro* immunization. *Ludwig Institute for Cancer Research*, Toronto Branch, Toronto, Ont., Mar. 10, 1986.
10. Neil, G.A. The pathophysiology of human colorectal cancer. *Medical Grand Rounds*, Princess Margaret Hospital, Toronto, Ont., Oct 18, 1987.
11. Neil, G.A. T cell mediated in vitro B cell stimulation. *Immunology Research Seminar*, Mt. Sinai Research Institute, Toronto, Ont., January 18, 1988.
12. Neil, G.A. The effect of anti-T cell receptor antibodies on CTL-mediated cytotoxicity. *Immunology Research Seminar*, University of Iowa Hospitals and Clinics, Iowa City, IA, January 23, 1988.
13. Neil, G.A. A new diagnostic test for the screening of adenomatous polyps and colorectal cancers. *Colorectal Cancer Research Group Meeting*, University of Toronto, Toronto, Ont., May 9, 1988.
14. Neil, G.A. Non-MHC restricted stimulation of antigen-specific B cells in splenic fragment cultures. *Gastroenterology Research Conference*, University of Iowa Hospitals and Clinics, Iowa City, IA, Oct. 8, 1988.
15. Neil, G.A. Experimental approaches to human colon cancer prevention. *Iowa Digestive Diseases Society Meeting*, University of Iowa Hospitals and Clinics, Iowa City, IA, Dec. 3, 1988.

16. Neil, G.A. Colon cancer prevention: state of the art. *Department of Internal Medicine Grand Rounds*, University of Iowa Hospitals and Clinics, Iowa City, IA, Jan. 19, 1989.
17. Neil, G.A. Non-MHC restricted stimulation of antigen-specific B cells in splenic fragment cultures. *Midwest Gut Club* meeting, Chicago, IL, Mar. 11, 1989.
18. Neil, G.A. Current concepts of stress ulcer pathophysiology and management. *Linn County Medical Society Meeting*, Cedar Rapids, IA, Apr. 19, 1989.
19. Neil, G.A. NSAID-induced gastropathy: pathophysiology and management. *Waterloo General Hospital Medical Association Meeting*. Waterloo, IA, Jul. 31, 1989.
20. Neil, G.A. Colonic polyp surveillance. *Advances in Internal Medicine*. University of Iowa Hospitals and Clinics, Iowa City, IA, Oct. 19, 1989.
21. Neil, G.A. Pseudomembranous colitis. *Fifth Annual Gastroenterology Nursing Conference: G.I. Emergencies*. Amana, IA, Nov. 17, 1989.
22. Neil, G.A. Activation of B lymphocytes in microgravity. *Digestive Diseases Research Conference*, University of Iowa Hospitals and Clinics, Iowa City, IA, Mar. 2, 1990.
23. Neil, G.A. Strategies for the prevention of colorectal cancer in primary practice. Family Practice Update. University of Iowa Hospitals and Clinics, Iowa City, IA, Mar. 8, 1990.
24. Neil, G.A. Molecular pathogenesis of colorectal cancer. *Iowa Digestive Diseases Society Meeting*. University of Iowa Hospitals and Clinics, Iowa City, IA, Mar. 31, 1990.
25. Neil, G.A. New approaches to the management of peptic ulcer disease. *Linn County Pharmacy Association*. Cedar Rapids, IA, May 22, 1990.
26. Neil, G.A. Celiac Disease. *Noon Conference*. University of Iowa Hospitals and Clinics, Iowa City, IA, May 22, 1990.
27. Neil, G.A. Immunological aspects of inflammatory bowel disease. *Mt. Sinai Research Institute Research Seminar*. Mt. Sinai Hospital, Toronto, Ont, May 31, 1990.
28. Neil, G.A. Inflammatory bowel disease. *Allergy and Immunology Grand Rounds*. University of Iowa Hospitals and Clinics, Iowa City, IA, Jun. 16, 1990.
29. Neil, G.A. Lymphocyte subpopulations in Crohns disease. *National Foundation for Ileitis and Colitis, Iowa Chapter Meeting*. Iowa City, IA, Jun. 20, 1990.
30. Neil, G.A. Gastrointestinal manifestations of AIDS. *Sixth Annual Gastroenterology Nursing Conference*. Amana, IA, Nov. 16, 1990.
31. Neil, G.A. Lymphocyte subpopulations in inflammatory bowel disease. *Gastroenterology Research Seminar*, Mar. 8, 1991 University of Iowa Hospitals and Clinics, Iowa City, IA.
32. Neil, G.A. New developments in the diagnosis and management of gastroesophageal reflux disease. *Linn County Medical Society Meeting*, Cedar Rapids, IA, March 20, 1991.
33. Neil, G.A. Peptic ulcer disease 1991. *Department of Internal Medicine Grand Rounds*, Apr. 13, 1991, St. Luke's Hospital, Sioux City, IA.

34. Neil, G.A. Lynch Syndrome. *Grand Rounds*, Sep. 8, 1991, Mercy Hospital, Iowa City, IA.
35. Neil, G.A. Human immune responses in the SCID-Hu chimera. *Immunology Research Seminar*, University of Iowa Hospitals and Clinics, Oct. 6, 1991, Iowa City, IA
36. Neil, G.A. *Helicobacter pylori*: is peptic ulcer an infectious disease? *Dubuque County Medical Society Meeting*, January 14, 1992, Dubuque, IA.
37. Neil, G.A. *Clostridium difficile*: what the primary care physician needs to know. *University of Iowa Visiting Professor Series*, January 23, 1992, Lutheran Hospital, Des Moines, IA.
38. Neil, G.A. Upper GI bleeding at the University of Iowa. *Gastroenterology Research Seminar*, March 12, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
39. Neil, G.A. *Helicobacter pylori* and peptic ulcer disease. *Iowa Digestive Diseases Society Meeting*, April 4, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
40. Neil, G.A. Antigen selection of hepatitis B surface antigen specific B cells in SCID-Hu-PBL mice and generation of hybridomas by electrofusion. *Department of Medicine Spring Research Day*, April 25, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
41. Neil, G.A. Production of human monoclonal antibodies using SCID-Hu-PBL chimeras. Invited Lecture. *Monoclonal Antibody Retreat*, May 1, 1992, University of Arizona Cancer Center, Tucson, AZ.
42. Neil, G.A. Viral hepatitis: prevention and therapy. *University of Iowa Office of CME Visiting Professor Series*, July 14, 1992, Broadlawns Medical Center, Des Moines, IA.
43. Neil, G.A. Viral Hepatitis: prevention and therapy. *University of Iowa Visiting Office of CME Professor Series*, September 4, 1992, Mercy Hospital, Davenport, IA.
44. Neil, G.A. Non-A Non-B Hepatitis: the agony and the ecstasC. *University of Iowa Department of Internal Medicine Grand Rounds*, September 10, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
45. Neil, G.A. Upper GI bleeding at the University of Iowa. *Iowa Digestive Diseases Society Meeting*, September 26, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
46. Neil, G.A. Analysis of lymphocyte subpopulations in inflammatory bowel diseases by 3-color flow cytometry. *Gastroenterology Research Seminar*, October 1, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
47. Neil, G.A. Analysis of lymphocyte subpopulations in inflammatory bowel diseases by 3-color flow cytometry. *Surrogate Markers of Human Disease, International Biotechnology Exposition and Scientific Conference*, October 12, 1992, San Francisco, CA.
48. Neil, G.A. NSAID-induced gastrointestinal toxicity. *Iowa Physician's Assistants Postgraduate Conference*, October 23, 1992, Holiday Inn, Iowa City, IA.
49. Neil, G.A. Screening for colorectal cancer: what the primary care physician needs to know. *Obstetrics and Gynecology Postgraduate Conference*, October 27, 1992, Iowa Memorial Union, University of Iowa, Iowa City, IA.

50. Neil, G.A. Analysis of lymphocyte subpopulations in inflammatory bowel diseases by 3-color flow cytometry. *Department of Internal Medicine Fall Research Day*, October 27, 1992, University of Iowa Hospitals and Clinics, Iowa City, IA.
51. Neil, G.A. NSAID-induced gastropathy. *University of Iowa Office of CME Visiting Professor Series*, November 18, 1992, VA Medical Center, Des Moines, IA.
52. Neil, G.A. Newer concepts in the pathogenesis and treatment of peptic ulcer disease. *University of Iowa Office of CME Visiting Professor Series*, November 26, 1992, Iowa Lutheran Medical Center, Des Moines, IA.
53. Neil, G.A. Peptic ulcer disease, 1993. *University of Iowa Office of CME Visiting Professor Series*, February 9, 1993, Broadlawns Medical Center, Des Moines, IA.
54. Neil, G.A. Screening for colorectal disorders. *American College of Physicians Scientific Meeting*, May 7, 1993, University of Iowa Hospitals and Clinics, Iowa City, IA.
55. Neil, G.A. Recent advances in peptic ulcer disease. *University of Iowa Office of CME Visiting Professor Series*, June 2, 1993, VA Medical Center, Des Moines, IA.
56. Neil, G.A. Colorectal cancer in the elderly. *Geriatric Summer Symposium* June 4, 1993, University of Iowa, Iowa City, IA.
57. Neil, G.A. Approach to abnormal liver function tests. *Gastroenterology in Family Practice*. June 19, 1993, Iowa Methodist Medical Center, Des Moines, IA.
58. Neil, G.A. Hepatitis C. *Gastroenterology in Family Practice*. June 19, 1993, Iowa Methodist Medical Center, Des Moines, IA.
59. Neil, G.A. *Helicobacter pylori*: sorting out the NIH Consensus Conference. April 6, 1994, *Midwest GI Medical Information Scientist Meeting*, Kansas City, MO.
60. Neil, G.A. Omeprazole plus antibiotics for the eradication of *H. pylori*. April 12, 1994, *Kentucky Gut Club*, Lexington, KY.
61. Neil, G.A. Hepatic fibrosis in SCID-Hu mice engrafted with PBL from patients with *Schistosomiasis japonica*. April 13, 1994, *Invited Lecture, University of Kentucky*, Lexington, KY.
62. Neil, G.A. Peptic ulcer - from chronicity to cure. June 23, 1994, *Invited Lecture, University of Saskatchewan*, Saskatoon, SK.
63. Neil, G.A. Peptic ulcer - from pH to Hp. October 7, 1994, *Invited Lecture, University of Iowa*, Iowa City, IA.
64. Neil, G.A. Omeprazole for maintenance of healing of erosive esophagitis. *Presentation to FDA GI Drugs Advisory Committee*. December 2, 1994, Bethesda, MD.
65. Neil, G.A. Omeprazole enhances cure of *H. pylori* infection by antimicrobials. *IBC Conference*. April 24, 1995, Philadelphia, PA.
66. Neil, G.A. Study design considerations for NSAID ulcer prophylaxis. *Antirheumatic Drug Guidelines/International Society for Rheumatic Therapy (ISRT) Workshop*. May 4, 1995, Scottsdale, AZ.

67. Neil, G.A. Omeprazole for maintenance of healed erosive esophagitis. *Astra Merck National Consultant's Meeting*. June 10, 1995, Colorado Springs, Co.
68. Neil, G.A. Omeprazole for maintenance of healed erosive esophagitis. *Astra Merck GERD Maintenance Launch Meeting*. Aug. 1, 1995, Atlanta, GA.
69. Neil, G.A. Omeprazole for maintenance of healed erosive esophagitis. *Astra Merck GERD Maintenance Launch Meeting*. Aug. 8, 1995, Atlanta, GA.
70. Neil, G.A. Astra Merck's commitment to GI diseases. *Astra Merck Regional Consultant's Meeting*. Sep. 23, 1995, Galena, IL.
71. Neil, G.A. The future of proton pump inhibitor research. *Astra Merck Regional Consultant's Meeting*. Sep. 24, 1995, Hilton Head, SC.
72. Neil, G.A. *H. pylori* eradication is a surrogate marker for prevention of duodenal ulcer recurrence. *Presentation to FDA Infectious Diseases and GI Drugs Advisory Committee*. October 26, 1995, Silver Spring, MD.
73. Neil, G.A. The natural history of duodenal ulcers in the *H. pylori* era. *Presentation to FDA Infectious Diseases and GI Drugs Advisory Committee*. October 26, 1995, Silver Spring, MD.
74. Neil, G.A. Omeprazole plus antibiotics for *H. pylori* eradication. *Cowen Health Conference*. Mar. 5, 1996, Boston, MA.
75. Neil, G.A. Omeprazole plus antibiotics for *H. pylori* eradication. *IBC Conference on H. pylori*, Apr. 1, 1996, Philadelphia, PA.
76. Neil, G.A. The role of the physician in drug development. *American College of Gastroenterology Fellow's Forum*, Apr. 13, 1996, Scottsdale, AZ.
77. Neil, G.A. The Astra Merck GERD home page. *NMHCC Internet Conference*. May 14, 1996, San Francisco, CA.
78. Neil, G.A. Training for global competition: needs and roles of multinational pharmaceutical companies. *The Future of Clinical Investigation. The American Society for Bone and Mineral Research*. Sep. 7, 1996, Seattle, WA.
79. Neil, G.A. Gastrointestinal drug development at Astra Merck. *Astra Merck Atlanta CU GI Regional Consultants Meeting*, Sep. 15, 1996, Sea Island, SC.
80. Neil, G.A. Do ulcers burn out or burn on? Managing duodenal ulcer disease in the *H. pylori* era. *Astra Merck Los Angeles CU GI Regional Consultants Meeting*, Sep. 21, 1996, Los Angeles, CA.
81. Neil, G.A. Do ulcers burn out or burn on? Managing duodenal ulcer disease in the *H. pylori* era. *Astra Merck Cincinnati CU GI Regional Consultants Meeting*, Sep. 28, 1996, Cincinnati, OH
82. Neil, G.A. *Helicobacter pylori*, acid suppression and atrophic gastritis. *Presentation to FDA GI Drugs Advisory Committee*. Nov. 4, 1996, Bethesda, MD.
83. Neil, G.A. Omeprazole plus antibiotics for the treatment of *H. pylori*-associated duodenal ulcer disease. *Gastroenterology Consultants Meeting*, Nov. 16, 1996, San Juan, Puerto Rico.



84. Neil, G.A. Do ulcers burn out or burn on? Managing duodenal ulcer disease in the *H. pylori* era. *IBC H. pylori Conference*, Jan. 27, 1997, Washington, DC.
85. Neil, G.A. Outcome of FDA hearing on omeprazole and atrophic gastritis. *Update on Atrophic Gastritis and Long-term Acid Suppression*. Heidelberg, Germany, Jan. 31, 1997.
86. Neil, G.A. Drug Development in the 1990's. Southern California GI Society Meeting, Los Angeles, CA, April 29, 1997.
87. Neil, G.A. Outcomes research in the pharmaceutical industry. Gastroenterology Research Group. Outcomes Research Conference. Philadelphia, PA, Oct. 8, 1997.
88. Neil, G.A. and Suchower, L. Developing drugs for *H. pylori* - the US perspective. DIA Meeting, Boston, MA, June 9, 1998.
89. Neil, G.A. The clinical investigation process – pharmaceutical industry perspective. American College of Gastroenterology meeting, Boston, MA, October 10, 1998.
90. Neil, G.A. Outcomes research – a vision for the future. Gastroenterology Research Group Conference on Outcomes Research, Tampa, FL, November 20, 1998.
91. Neil, G.A. Drug development: An industry perspective. American association for the Study of Liver Disease research Conference on Clinical Trials, Orlando, FL, May 15, 1999.
92. Neil, G.A. A PhRMA - NIH – FNIH - FDA Biomarkers Consortium. (Session Chair and Speaker). 19<sup>th</sup> Annual Drug Information Association Euro Meeting, Vienna, Austria, March 27, 2007.
93. Neil, G.A. Innovation and Enhancing R&D Productivity. Panel Discussion. Health Care Industry Association, Columbia Business School, Manhattan, NY, March 30, 2007.
94. Neil, G.A. Panel member. Institutional policy and practice supporting translational medicine. TransMed Forum, St. Louis, MO, September 10, 2007.
95. Neil, G.A. Translational Research: From Science to Services. Global Health in the 21st Century: A roadmap for international collaboration. Italian Embassy, Washington, DC, October 11, 2007.
96. Neil, G.A. Body computing: Completing the Loop: How to truly integrate wireless physiologic monitoring into our world. First USC Body Computing Conference. University of Southern California, Los Angeles, CA, October 26, 2007.
97. Neil, G.A. Conflict of Interest – an industry perspective. Institute of Medicine, Washington, DC, November 6, 2007.
98. Neil, G.A. Benefit Risk Assessment, an industry perspective. Assessing Drug Benefits and Risks in Regulatory Decisions: Framing the need, Evaluating the tools, and Deciding next steps. Joint FDA, PhRMA, BIO Working Conference. FDA, Washington, DC, November 6, 2007.
99. Neil, G.A. Transforming Health – fulfilling the promise of research. Research America/PhRMA innovation conference. Washington, DC, November 16, 2007.

100. Neil, G.A. Personalized Medicine. Perspectives from the Pharmaceutical and Diagnostics Industry. Harvard Medical School, Boston, MA, November 29, 2007.
101. Neil, G.A. Panel discussion. Redesigning the clinical effectiveness research paradigm: innovation and practice-based approaches. A learning healthcare workshop. Institute of Medicine Roundtable on Evidence Based Medicine. The National Academy of Sciences, Washington DC, December 13, 2007.
102. Neil, G.A. Invited lecture and session chair. Regulations and Reimbursement – 2 sides of the same coin? CMR Workshop. Woodlands Park Hotel, Cobham, Surrey, UK. January 16, 2008.
103. Neil, G.A. Invited lecture. Pharma R&D 2008. Columbia Business School. New York, NY, January 30, 2008.
104. Neil, G.A. Invited lecture and panel discussion. University-Industry Relationships that Work. American Association of Universities, Senior Research Officers Meeting. La Jolla, CA, March 11, 2008.
105. Neil, G.A. Research!America 2008 National Forum Panel Discussion. Washington, DC, March 18, 2008.
106. Neil, G.A. Invited keynote address. The Life Sciences Boom. Are Innovation and Transformation Enough to Maintain Massachusetts Edge? Executive Council, Boston, MA, April 10, 2008.
107. Neil, G.A. COSAT – what's new? Rutgers University. New Brunswick, NJ, April 23, 2008.
108. Neil, G.A. Prescriptions for Health Care Reform. Presentation and panel discussion. St. Joseph's University Business School, Philadelphia, PA, May 16, 2008.
109. Neil, G.A. Biomarkers – are we there yet? Hever 13, St. Michael's, MD, May 17, 2008.
110. Neil, G.A. Sentinel Network Governance Issues, Panel Discussion, Brookings Institute, Washington, Dc, June 13, 2008.
111. Neil, G.A. CEO Forum on Balancing Benefits and Risks, Panel Moderator, BIO 2008, San Diego, CA, June 17, 2008.
112. Neil, G.A. The Challenges of an Aging Population, Panel Discussion, BIO 2008, San Diego, CA, June 18, 2008.
113. Neil, G.A. The Biomarkers Consortium: Developing and Validating High Impact Biomarkers for Drug Development Through Public-Private Partnerships. Biomarkers Super Session, BIO 2008, San Diego, CA, June 19, 2008.
114. Neil, G.A. Precompetitive Collaboration. Institute of Medicine Forum on Drug Development, Washington, DC, June 24, 2008.
115. Neil, G.A. The Biomarkers Consortium. Critical Path Update, 44<sup>th</sup> DIA Meeting, Boston, MA, June 25, 2008.
116. Neil, G.A. Qualification of Biomarkers. Drug Discovery and Development. Boston, MA, August 5, 2008.

117. Neil, G.A. Center for Biomedical Innovation: Drug Safety Symposia. Panel Moderator. Cambridge, MA October 23, 2008.
118. Neil, G.A. Body Computing Conference 2.0. For the People: How to Make Body Computing Work in the Real World, Panel member. Los Angeles, CA, October 24, 2008.
119. Neil, G.A. MIT Research and Development Conference. Panel Discussion: Industry-government research cooperation in response to regional research trends. Cambridge, MA, October 28, 2008.
120. Neil, G.A. Massachusetts Biotechnology Council. J&J Overview. Cambridge, MA, November 6, 2008.
121. Neil, G.A. FDA Sentinel Initiative Meeting. Panelist and Breakout session leader. Washington, DC, December 16, 2008.
122. Neil, G.A. Annual Conference on Drug Development. External Innovation. Austin, TX, Feb 11, 2009.
123. Neil, G.A. Brookings Institute Conference: Comparative Effectiveness, Panel Discussion. Washington, DC, June 9, 2009
124. Neil, G.A. Harvard Infectious Disease Meeting; Panelist. Boston, MA, October 15, 2009
125. Neil, G.A. International Health Care Industry Forum 2009: Plenary Sessions Opening Remarks. Beijing, China November 4, 2009.
126. Neil, G.A. Beijing International Health Care Industry Forum: 2009 Keynote address: Pharmaceutical Industry Challenges 2009 Beijing, China, November 5, 2009.
127. Neil, G.A. Partnering for Cures. Regulatory science. Panelist. New York, NY, Dec 3, 2009.
128. Neil, G.A. Royal Society of Pharmaceuticals: Regenerative Medicine, a pharma industry perspective. London, UK, February 8, 2010.
129. Neil, G.A. International Conference on Drug Development. The Biomarkers Consortium Update. Austin, TX, February 24, 2010.
130. Neil, G.A. CMR Workshop Review and Reimbursement Session Chair: The Changing Face of Health Care in the USA. Washington, DC, March 23, 2010.
131. Neil, G.A. CMR Workshop Review and Reimbursement. What is the pathway to the future of sustainable drug development? Washington, DC, March 23, 2010.
132. Neil, G.A. Milken Global Conference 2010. Accelerating cures by building a more effective FDA. April 27, 2010.
133. Neil, G.A. BIO 2010. Regenerative Medicine: A Pharma Guy's Personal Perspective. Chicago, IL May 3, 2010
134. Neil, G.A. Wireless Life Sciences Alliance Summit. A conversation about physician adoption of wireless health applications. La Jolla, CA, May 10, 2010.
135. Neil, G.A. KOTRA. External Innovation. Seoul, Korea, May 18, 2010

136. Neil, G.A. World Pharmaceutical Forum (China) Keynote address: J&J External Innovation Strategy, Shanghai, China May 20, 2010.
137. Neil, G.A. Biopharm America. From the Trenches: Partnering War Stories. Boston, MA, September 16, 2010.
138. Neil, G.A, Program in Pharmaceutical Management, Rutgers Business School. Drug Development. Newark, NJ, October 7, 2010.
139. Neil, G.A. Brookings Institute Conference Accelerating Health Care Innovation to Achieve System-Wide Impact. Washington, DC, October 18, 2010.
140. Neil, G.A. Life Science Alley. New Paradigms of Innovation: A Personal Perspective. Minneapolis, MN, December 8, 2010.
141. Neil, G.A. PhRMA Board of Directors. PhRMA Foundation Review. Washington, DC, November 8, 2010.
142. Neil, G.A. Faster Cures Annual Meeting. Bridging the Gap. Panelist. New York, NY, December 15, 2010.
143. Neil, G.A. JP Morgan Conference Biotech Showcase. Balancing Innovation and Risk: Does Big Pharma want what you have? San Francisco, January 12, 2011.
144. Neil, G.A. Archipelago Meeting, University of Toronto. Pharma R&D Challenges. Toronto, Canada. February 16, 2011.
145. Neil, G.A. Forum for Sustainable Health. Pharma Industry R&D. Phoenix AZ, February 17, 2011.
146. Neil, G.A. AIMBE Meeting. Keynote Address: Industry Academic Interactions. Washington, DC, February 20, 2011.
147. Neil, G.A. AUTM Meeting. Panel: Managing Innovation. Las Vegas, NV, February 28, 2011.
148. Neil, G.A. NIH PPCCC meeting. Public Private Partnerships: Industry Perspective. Bethesda, MD, March 17, 2011.
149. Neil, G.A. ISSCR Global Forum. Stem Cell Therapy and Pharmaceuticals. Half Moon Bay, CA, March 18, 2011.
150. Neil, G.A. World Healthcare Congress. Regulatory Science. National Harbor, MD April 4, 2011.
151. Neil, G.A, Program in Pharmaceutical Management, Rutgers Business School. Drug Development. Newark, NJ, April 8, 2011.
152. Neil, G.A. PhRMA Annual Meeting. Bringing Science to Life. Jersey City, MD, April 14, 2011.
153. Neil, G.A. NAS Workshop. Impacts of Research on Decision-Making & Public Behavior. Washington, DC, April 19, 2011.
154. Neil, G.A. Rutgers Annual Healthcare Symposium, Rutgers Business School. Panelist, Pharmaceutical Innovation. Newark, NJ, April 21, 2011.

155. Neil, G.A. NIH Gaining Access to Approved Drugs & Abandoned Compounds-Crafting an Agreement, Session Chair and Panelist, Bethesda, MD, April 22, 2011
156. Neil, G.A., US/Russia Scientific Forum, Russian Academy of Science. Johnson and Johnson overview and investments in Russia. Moscow, Russia, April 25, 2011.
157. Neil, G.A. Milken Institute Global Conference. Regulatory Science. Panelist. Beverly Hills, CA, May 2, 2011.
158. Neil, G.A. Hever 2011. Public Private Partnerships. St. Michaels, MD, May 14, 2011.
159. Neil, G.A. BIO Israel. Keynote address: Perspectives on the Biopharmaceutical Industry – 2011 and Beyond. Tel Aviv, Israel, May 25, 2011.
160. Neil, G.A. Drug Safety Surveillance, Brookings Institute. Industry Perspective. Washington, DC, June 1, 2011.
161. Neil, G.A. NLM/FNLM Clinical Trials Conference. Clinical Trials: an Industry Perspective. Washington, DC. June 7, 2011.
162. Neil, G.A, Program in Pharmaceutical Management, Rutgers Business School. Drug Development. Newark, NJ, July 14, 2011.
163. Neil, G.A. SATAC Committee, J&J BOD. External Innovation. New Brunswick, NJ. July 18, 2011.
164. Neil, G.A. BIO 2011. Biomarkers Consortium: an Industry Perspective. Washington, DC, June 27, 2011.
165. Neil, G.A. Regenerative Medicine Satellite Conference, BIO 2011. Regenerative Medicine at J&J. Washington, DC, June 28, 2011.
166. Neil, G.A. BIO 2011. Innovation in Israel, an Industry Perspective. Washington, DC, June 29, 2011.
167. Neil, G.A. Biopharm America 2011. Pharma Venture Capital Roundtable. Boston, MA, September 8, 2011.
168. Neil, G.A. Biopharm America 2011. Regenerative Medicine, Panelist. Boston, MA, September 9, 2011.
169. Neil, G.A. Diversity in Clinical Trials: the J&J experience. National Minority Quality Forum Dinner. Washington, DC, September 23, 2011.
170. Neil, G.A., Dialogues on Diversifying Clinical Trials: Successful strategies for engaging women and minorities in clinical trials. Panelist. FDA Clinical Trials Conference, Washington, DC, September 23, 2011.
171. Neil, G.A. Supporting Safety Science Methods Research and Development. FDA Sentinel Initiatives Strategic Review. Brookings Institute, Washington, DC, September 27, 2011.
172. Neil, G.A. Supporting Safety Science Methods R&D. Brookings Institute, Washington DC, October 25, 2011.

173. Neil, G.A. Perspectives on the Biopharmaceutical Industry 2011 and Beyond. Keynote Address. 15<sup>th</sup> Beijing International Healthcare Industry Forum, Beijing, China, November 1, 2011.
174. Neil, G.A. and Landis, S. Session Co-Chairs. Target Validation Workshop. National Institutes of Health, Bethesda, MD, Nov 3-4, 2011.
175. Neil, G.A. Drug Development Overview. PhRMA. Washington, DC, November 11, 2011.
176. Neil, G.A. Panel participant. Active Surveillance Council Meeting #4. Brookings Institute, Washington, DC, November 30, 2011.
177. Neil, G.A. Roundtable participant. Coverage with evidence determination. Brookings Institute, Washington, DC, December 8, 2015.
178. Neil, G.A. Patient-centric drug development. Economist Intelligence Unit. Research Advisory Board. New York, NY, December 13, 2011.
179. Neil, G.A. Panelist. Accelerated drug approval. Brookings Institute. Washington, DC, December 15, 2011.
180. Neil, G.A. Invited lecture. External Innovation, the J&J approach. University Industry Demonstration Partnership, New Brunswick, NJ. April 23, 2012.
181. Neil, G.A. Keynote lecture. A new approach to pharmaceutical R&D. Accenture Pharmaceutical R&D Day. Philadelphia, PA. April 25, 2012.
182. Neil, G.A. Keynote address. Biopharmaceutical challenges and solutions 2012. Shanghai Bioforum. Shanghai, China. May 10, 2012.

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
 Witness Disclosure Requirement - "Truth in Testimony"  
 Required by House Rule XI, Clause 2(g)

1. Your Name: <u>GARRY A. NEIL</u>		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No <input checked="" type="checkbox"/>
3. Are you testifying on behalf of an entity that is not a government entity?	Yes	No <input checked="" type="checkbox"/>
4. Other than yourself, please list which entity or entities you are representing:  <u>None</u>		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011:  <u>None</u>		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing:  <u>N/A</u>		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:		
9. Please attach your curriculum vitae to your completed disclosure form.  <u>ATTACHED</u>		

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

5/18/14